Overview

A Safety and Efficacy Study of Sufentanil Transdermal System in Patients With Chronic Pain Due to Cancer

Status:
Withdrawn
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
The study hypothesis is that the safety and efficacy of sufentanil following transdermal application is comparable to sustained release morphine sulphate tablets in patients with chronic pain due to cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Labtec GmbH
Treatments:
Morphine
Sufentanil